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The phenotypic heterogeneity of PID leads to diagnostic difficulty, and almost certainly to an 79 underestimation of its true incidence. Our cohort reflects this heterogeneity, though it is dominated by 80 adult onset, sporadic antibody deficiency associated PID (AD-PID: comprising Common Variable  81 Immunodeficiency (CVID), Combined Immunodeficiency (CID) and isolated antibody deficiency). 82
Identifying a specific genetic cause of PID can facilitate definitive treatment including haematopoietic 83 stem cell transplantation, genetic counselling, and the possibility of gene-specific therapy 2-4 while 84 contributing to our understanding of the human immune system 5 . Unfortunately, only 29% of patients 85 with PID receive a genetic diagnosis 6 . The lowest diagnosis rate is in patients who present as adults, 86 have no apparent family history, and in whom matching the clinical phenotype to a known genetic cause 87 is difficult, as the latter can be surprisingly variable even in patients with the same genetic defect (in the 88 UK PID cohort 78% of cases are adult and 76% sporadic 6 ). Moreover, while over 300 monogenic causes 89 of PID have been described 7 , the genotype-phenotype correlation in PID is complex. In CVID, for 90 example, pathogenic variants in TACI (TNFRSF13B) occur in 10% of patients but typically have low 91 disease penetration, appearing to act as disease modifiers 8 . Furthermore, a common variant analysis of 92 CVID identified two disease-associated loci, raising the possibility that common variants may impact 93 upon clinical presentation 9 . We therefore investigated whether applying WGS across a "real world" PID 94 cohort might illuminate the complex genetics of the range of conditions collectively termed PID. were less frequent, in part reflecting prior genetic testing of more severe cases ( Supplementary Fig. 1 ).
104
Clinical phenotypes were dominated by adult-onset sporadic AD-PID: all had recurrent infections, 28% 105 had autoimmunity, and 8% had malignancy ( Fig. 1a- We observed divergence from an expected clinical phenotype for causal variants in 14 genes: for 122 instance, only 4 of the 8 STAT1 patients had the pathognomonic chronic mucocutaneous candidiasis 13, 14 .
123
A more remarkable example of phenotypic complexity was the case of a 40 year-old patient presenting 124 with specific antibody deficiency and a premature stop variant at Arg328 in X-linked IL2RG, a defect 125 expected to cause absent T and NK cells and death in infancy. We found that the mild phenotype could 126 4 be ascribed to several independent somatic changes that reversed the premature stop codon, restoring 127 both T and NK cell lineages ( Fig. 1d and Supplementary Fig. 2 ). 128 129
Since many PID-associated genes were initially discovered in a small number of typically familial cases, it 130 is perhaps not surprising that the phenotypes described do not reflect true clinical diversity. Thus, a 131 cohort-based WGS approach to PID can provide a significant diagnostic yield even in a predominantly 132 pre-screened and sporadic cohort, allows diagnoses which are not constrained by pre Fig.  155 3). 156
157
Identification of regulatory elements contributing to PID 158 159
Sequence variation within non-coding regions of the genome can have profound effects on spatial and 160 temporal gene expression 17 and would be expected to contribute to PID susceptibility. We combined 161 rare variant and deletion events with a tissue-relevant catalogue of cis-regulatory elements (CREs) 18 162 generated using promoter capture Hi-C (pcHi-C) 19 in matching tissues to prioritise putative causal PID 163 genes (Fig. 2a) . Being underpowered to detect single nucleotide variants affecting CREs
20
, we limited our 164 initial analysis to rare structural variants (SV) overlapping exon, promoter or 'super-enhancer' CREs of 165 known PID genes. No homozygous deletion events affecting CREs were identified, so we sought CRE SV 166 deletions that might cause disease through a candidate compound heterozygote (cHET) mechanism with 167 either a heterozygous rare coding variant or another SV in a pcHi-C linked gene (Fig. 2a) . Out of 22,296 168 candidate cHET deletion events, after filtering by MAF, functional score and known PID gene status, we 169 obtained 10 events; the functional follow-up of three is described (Fig. 2b) .
171
The LRBA and DOCK8 cHET variants ( Supplementary Fig. 4) were functionally validated; the former was 172 demonstrated to result in impaired surface CTLA-4 expression on Treg cells (Supplementary Fig. 5 ) 173 whilst the latter led to DOCK8 deficiency as confirmed by flow cytometry (data not shown). Although in 174 these two cases SV deletions encompassed both non-coding CREs and coding exons, the use of WGS PID 175 cohorts to detect a contribution of CREs confined to the non-coding space would represent a major 176 advance in PID pathogenesis and diagnosis. ARPC1B fulfilled this criterion, with its BeviMed association 177 partially driven by a patient cHET for a novel p.Leu247Glyfs*25 variant resulting in a premature stop, 178 and a 9Kb deletion spanning the promoter region including an untranslated first exon (Fig. 2c) that has 179 no coverage in the ExAC database (http://exac.broadinstitute.org). Two first-degree relatives were 180 heterozygous for the frameshift variant, and two for the promoter deletion (Fig. 2d) . Western blotting 181 demonstrated complete absence of ARPC1B (Fig. 2e ) and, consistent with previous reports 21 , raised 182 ARPC1A in platelets. ARPC1B mRNA was almost absent from mononuclear cells in the cHET patient and 183 reduced in a clinically unaffected sister carrying the frameshift mutation (Fig. 2f ). An allele specific 184 expression assay demonstrated that the promoter deletion essentially abolished mRNA expression ( Fig.  185  2g, Fig. 3a) and a particularly strong correlation with age ( Supplementary Fig. 6 23 and identifying several PID cases with short 199 telomeres (Fig. 3b) . Given that disruption of telomerase genes can cause PID 24 , we looked for potentially 200 damaging coding variants in known telomere deficiency genes 25 in these PID cases, identifying 3 subjects 201 with novel variants potentially causative for telomerase deficiency (Fig. 3b) . One had a homozygous 202 defect in telomerase reverse transcriptase (TERT), a subunit of the telomerase complex. Two male 203 siblings were found to have a hemizygous variant in dyskerin (DKC1), known to be associated with PID 204 and X-linked dyskeratosis congenita 26 (Fig. 3c) . Therefore, WGS telomere length estimation can be used 205 as an effective approach to identify PID patients with novel variants causing telomere shortening. 206 207 GWAS of the WGS cohort reveals novel PID-associated loci 208 209
The diverse clinical phenotype and variable within-family disease penetrance of PID may be in part due 210 to stochastic events (e.g. unpredictable pathogen transmission) but may also have a genetic basis. We 211 therefore performed a GWAS of common SNPs (MAF>0.05), restricted to 733 AD-PID cases (Fig. 1a) to 212 reduce phenotypic heterogeneity, and 9,225 unrelated NBR-RD controls. We confirmed the known MHC 213 association and identified additional loci with suggestive association (Fig. 4a, Supplementary Fig. 7 Fig. 1) , for which the lead p.Cys104Arg 216 variant has been previously reported 27 . 217
To increase power, we conducted a fixed effect meta-analysis of the AD-PID GWAS with summary 218 statistics data from an ImmunoChip study of 778 CVID cases and 10,999 controls 9 (Fig. 4a,  219 Supplementary Table 5 ). This amplified the MHC and 16p13.13 associations 9 , found an additional locus 220 6 at 3p24.1 within the promoter region of EOMES (Extended Data Fig. 2) , and a suggestive association at 221 18p11.21 proximal to PTPN2 (Extended Data Fig. 3 ). Conditional analysis of the MHC locus revealed 222 independent signals at the Class I and Class II regions ( Supplementary Fig. 8 ), driven by classical alleles 223 HLA-B*08:01 and HLA-DRB1*15:01 (Methods) with amino-acid changes known to impact upon peptide 224 binding (Fig. 4b) . 225 We next sought to examine, genome-wide, the enrichment of non-MHC AD-PID associations in 9 other 226 diseases (Extended Data Table 1 ). We found significant enrichment for allergic (e.g. asthma) and 227 immune-mediated diseases (e.g. Crohn's disease), which was not evident in Type 2 diabetes or coronary 228 artery disease (Fig. 4c) . This suggests that the common variant association between PID and other 229 immune-mediated diseases extends beyond the 4 genome-wide loci to multiple sub-genome-wide 230 associations, and that dysregulation of common pathways contributes to susceptibility to both. 231
Understanding the impact of these interrelationships will be a complex process. For example, while 232 variants in the HLA-DRB1 and 16p13.13 loci increase the risk of both PID and autoimmunity, those at the 233 EOMES locus predispose to PID but protect from rheumatoid arthritis 28 (Extended Data Fig. 2 . In patient T cell blasts SOCS1 was deficient and IFN-γ induced STAT1 254 phosphorylation was abnormal (Fig. 4e) , consistent with SOCS1 haploinsufficiency causing PID. The 255 patient also carries the SOCS1 pcHiC-linked 16p13.13 risk-allele identified in the AD-PID GWAS 256 (Extended Data Fig. 4 ). Long read sequencing using Oxford Nanopore technology showed this to be in 257 trans with the novel SOCS1-truncating variant (Methods); such compound heterozygosity raises the 258 possibility that common and rare variants may combine to cause disease. 259 260 A more detailed example of an interplay between rare and common variants is provided by a family 261 containing a novel PTPN2 premature stop-gain at p.Glu291 and a common autoimmunity-associated 262 variant (Fig. 4f) . PTPN2 encodes the non-receptor T-cell protein tyrosine phosphatase (TC-PTP) protein, 263 that negatively regulates immune responses by dephosphorylation of the proteins mediating cytokine 264 signalling. PTPN2 deficient mice are B cell lymphopenic 33,34 , while inducible haematopoietic deletion of 265 PTPN2 leads to B and T cell proliferation and autoimmunity 35 . The novel truncating variant was 266 identified in a "sporadic" index case presenting with CVID at age 20; he had B lymphopenia 267 ( Supplementary Fig. 9 ), low IgG, symmetrical rheumatoid-like polyarthropathy, severe recurrent 268 7 bacterial infections, splenomegaly and inflammatory lung disease. His mother, also heterozygous for the 269 PTPN2 truncating variant, had systemic lupus erythematosus (SLE), insulin-dependent diabetes mellitus 270 diagnosed at 42, hypothyroidism and autoimmune neutropenia (Supplementary Discussion). Gain-of-271 function variants in STAT1 can present as CVID (Supplementary Table 3 ) and TC-PTP, like SOCS1, 272 reduces phosphorylated-STAT1 (Fig. 4g) . Both mother and son demonstrated reduced TC-PTP expression 273 and STAT1 hyperphosphorylation in T cell blasts, similar to the SOCS1 haploinsufficient patient above 274 and to known STAT1 GOF patients; abnormalities that were more pronounced in the PTPN2 index case 275 (Fig. 4h) . 276 277
The index case, but not his mother, carried the G allele of variant rs2847297 at the PTPN2 locus, an 278 expression quantitative trait locus (eQTL) 36 previously associated with rheumatoid arthritis 37 . His 279 brother, generally healthy apart from severe allergic nasal polyposis, was heterozygous at rs2847297 280 and did not inherit the rare variant (Fig. 4f) . Allele-specific expression analysis demonstrated reduced 281 PTPN2 transcription from the rs2847297-G allele, explaining the lower expression of TC-PTP and greater 282 persistence of pSTAT1 in the index case compared to his mother (Fig. 4i ). This in turn could explain the 283 variable disease penetrance in this family, with PTPN2 haploinsufficiency alone driving autoimmunity in 284 the mother, but with the additional impact of the common variant on the index case causing 285 immunodeficiency (and perhaps reducing the autoimmune phenotype). MDT decided that they were likely to be pathogenic and contribute to the phenotype, they were also 578 reported and counted towards the overall diagnostic yield. All variants and breakpoints of large 579 deletions reported in this study were confirmed by Sanger sequencing using standard protocols. 580
. Antibody deficiency (AD-PID) GWAS identifies common variants that mediate disease risk

581
BeviMed 582
We used BeviMed 1 to evaluate the evidence for association between case/control status and rare 583 variant allele counts in each gene. We inferred a posterior probability of association (PPA) under 584
Mendelian inheritance models (dominant and recessive), and different variant selection criteria 585 ("moderate" and "high" impact variants based on functional consequences predicted by the Variant 586 Effect Predictor 39 ). All genes were assigned the same prior probability of association with the disease of 587 0.01, regardless of their previously published associations with an immune deficiency phenotype. Genes 588 for which BeviMed inferred a PPA to be >=0.18 when summed over all four combinations of inheritance 589 model and variant selection criteria (each configuration being given a prior probability of association of 590 0.0025) are shown in Fig. 1f . Given each of the association models, the posterior probability that each 591 variant is pathogenic is also computed. We used a variant-level posterior probability of pathogenicity 592 >0.2 to select potentially pathogenic missense variants in known PID genes to report back. 593
594
Telomerecat 595
Average telomere length was calculated from whole-genome sequence data using Telomerecat, as 596 reported previously
22
. Batch differences caused by changes in sequencing platform differences were 597 normalised by using a linear model. The linear model was defined as: 598 599 15 where β are regression coefficients, and batch represents a dummy variable denoting the plate a sample 600 was sequenced on. For each plate the relevant coefficient was subtracted from all of the observed 601 telomere lengths within each plate. 602
After adjusting for batch effects, telomere length was compared to age in 3,313 NBR-RD subjects. We 603 obtained a strong negative correlation with age (r = −0.56, Pearson's correlation), thus validating 604
Telomerecat as a reliable method for estimating telomere lengths. We found that each year of 605 additional age was equivalent to a 33bp deterioration in telomere length (Supplementary Fig. 6 ).
606
Although this observed negative correlation is well established within the literature, we obtain a 607 particularly high correlation with our method, which could be partly driven by the wide age range of our 608 sample set. 609
To normalise telomere lengths for comparison of samples from disparate age and gender, the following 610 linear model was fitted to the data using age as a continuous variable and gender as a dummy variable: 611
612
The relevant residuals produced by the cubic model were subtracted from the mean telomere length of 613 the cohort. These adjusted telomere lengths were used in the GWAS analysis. 614
To assess for monogenic causes of telomere shortening, subjects were identified within the PID cohort 615 that had telomere lengths below the 10 th centile of age adjusted values and had hemizygous or 616 homozygous SNVs that occurred gnomAD AF<0.001 in TERC, TERT, NHP2, TINF2, NOP10, PARN, ACD, 617 WRAP53, CTC1, RTEL1 or DKC1 genes. 618 619 AD-PID GWAS 620 GWAS was performed both on the whole PID cohort (N cases = 886) and on a subset of AD-PID cases (N 621 cases = 733); here we present the results of the latter analysis, which was cleaner and less noisy despite 622 a reduced sample size. We used 9225 unrelated samples from non-PID NBR-RD cohorts as controls. 623
Variants were selected from a merged VCF file were filtered to include bi-allelic SNPs with overall 624 MAF>=0.05 and minOPR=1 (100% pass rate). We ran PLINK logistic association test under an additive 625 model using the read length, sex, and first 10 principal components from the ethnicity analysis as 626 covariates. After filtering out SNPs with HWE p<10 -6
, we were left with the total of 4,993,945 analysed 627
SNPs. There was minimal genomic inflation of the test statistic (lambda = 1.027), suggesting population 628 substructure and sample relatedness had been appropriately accounted for. The only genome-wide 629 significant (p<5x10 -8 ) signal was at the MHC locus, with several suggestive (p<1x10 -5 ) signals 630 (Supplementary Fig. 7) . We repeated the analysis with more relaxed SNP filtering criteria using 631 MAF>=0.005 and minOPR>0.95. The only additional signal identified were the three TNFRSF13B variants 632 shown in Extended Data Fig. 1.  633 We obtained summary statistics data from the Li et al. CVID Immunochip case-control study 9 and 634 performed a fixed effects meta-analysis on 95,417 variants shared with our AD-PID GWAS. For each of 635 the genome-wide and suggestive loci after meta-analysis, we conditioned on the lead SNP by including it 636 as an additional covariate in the logistic regression model, to determine if the signal is driven by the 637 single or multiple hits at those loci. Only the MHC locus showed evidence of multiple independent 638 signals ( Supplementary Fig. 8 ). 639
MHC locus imputation 641
We imputed classical HLA alleles using the method implemented in the SNP2HLA v1. 
729
Here * = 5 are flat prior probabilities for a randomly selected variant from the genome to be causal 730 and we use the value 1x10 -4 47 . We sum over these PPCV within an LD block, to obtain the posterior 731 probability that contains a single causal variant (PPCB). 732
To compute enrichment for trait , we convert PPCBs into a binary label by applying a threshold such 733 that % > 0.95. We apply these block labels for trait , to PPCBs (computed as described above) for 734 our AD-PID cohort GWAS, using them to compute a non- IL12RB1  IL2RG  IRF8  MAGT1*  PIK3CD  RAG1  RAG2  RFXANK  STK4*  TERT  TINF2*  TTC37  TTC7A  XIAP 
